Philadelphia CyberKnife has been credentialed by the Radiological Physics Center (RPC), an organization funded by the National Cancer Institute (NCI) to provide quality assurance auditing of dosimetry practices at institutions participating in NCI cooperative clinical trials.
The RPC assures the NCI and cooperative clinical trial groups that all participating institutions have the equipment, personnel and procedures necessary to administer radiation doses that are clinically comparable to those of other participating institutions.
“We are excited about the RPC credentialing, as it will allow us to participate in more national clinical trials analyzing the effects and efficacy of stereotactic body radiation therapy for adult cancers,” said Jun Yang, Ph.D, chief medical physicist at Philadelphia CyberKnife.
Philadelphia CyberKnife is a participating institution in national clinical trials conducted by the Radiation Therapy Oncology Group, one of nine cooperative clinical trials groups in the U.S. Philadelphia CyberKnife is one of several notable research institutions participating in the RTOG 0938 protocol – A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer-RTOG/CCOP Study.
Other protocols in which Philadelphia CyberKnife is a participating clinical investigator include:
- RTOG 0618 Protocol: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer
- RTOG 0813 Protocol: Seamless Phase I/II Study of Stereotactic Body Radiation Therapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients